Intellia Therapeutics, Inc. (0JBU.L)
USD 9.2
(6.36%)
USD 9.2
(6.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -515.29 Million USD | -12.47% |
| 2022 | -458.16 Million USD | -71.05% |
| 2021 | -267.85 Million USD | -96.11% |
| 2020 | -136.58 Million USD | -28.41% |
| 2019 | -106.36 Million USD | -17.06% |
| 2018 | -90.87 Million USD | -30.64% |
| 2017 | -69.55 Million USD | -116.28% |
| 2016 | -32.15 Million USD | -139.83% |
| 2015 | -13.4 Million USD | -156.58% |
| 2014 | -5.22 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -114 Million USD | 18.51% |
| 2024 Q2 | -139.04 Million USD | -21.96% |
| 2023 Q2 | -132.33 Million USD | -18.2% |
| 2023 FY | -515.29 Million USD | -12.47% |
| 2023 Q4 | -139.89 Million USD | -6.7% |
| 2023 Q1 | -111.95 Million USD | -1.7% |
| 2023 Q3 | -131.1 Million USD | 0.93% |
| 2022 Q1 | -144.24 Million USD | -79.38% |
| 2022 Q4 | -110.08 Million USD | -4.32% |
| 2022 Q3 | -105.53 Million USD | -7.35% |
| 2022 Q2 | -98.3 Million USD | 31.85% |
| 2022 FY | -458.16 Million USD | -71.05% |
| 2021 Q3 | -71.99 Million USD | -4.31% |
| 2021 Q4 | -80.41 Million USD | -11.7% |
| 2021 FY | -267.85 Million USD | -96.11% |
| 2021 Q1 | -46.42 Million USD | -9.5% |
| 2021 Q2 | -69.01 Million USD | -48.66% |
| 2020 Q4 | -42.39 Million USD | -50.88% |
| 2020 FY | -136.58 Million USD | -28.41% |
| 2020 Q1 | -33.04 Million USD | -11.01% |
| 2020 Q3 | -28.1 Million USD | 14.93% |
| 2020 Q2 | -33.03 Million USD | 0.04% |
| 2019 Q3 | -25.32 Million USD | 7.76% |
| 2019 FY | -106.36 Million USD | -17.06% |
| 2019 Q1 | -23.8 Million USD | -14.76% |
| 2019 Q4 | -29.77 Million USD | -17.54% |
| 2019 Q2 | -27.46 Million USD | -15.33% |
| 2018 Q4 | -20.74 Million USD | 13.91% |
| 2018 FY | -90.87 Million USD | -30.64% |
| 2018 Q3 | -24.09 Million USD | -2.14% |
| 2018 Q2 | -23.59 Million USD | -5.19% |
| 2018 Q1 | -22.43 Million USD | 9.25% |
| 2017 FY | -69.55 Million USD | -116.28% |
| 2017 Q3 | -15.87 Million USD | 0.89% |
| 2017 Q2 | -16.01 Million USD | -23.7% |
| 2017 Q4 | -24.71 Million USD | -55.69% |
| 2017 Q1 | -12.94 Million USD | -19.65% |
| 2016 FY | -32.15 Million USD | -139.83% |
| 2016 Q4 | -10.82 Million USD | -40.6% |
| 2016 Q3 | -7.69 Million USD | -10.81% |
| 2016 Q2 | -6.94 Million USD | -3.76% |
| 2016 Q1 | -6.69 Million USD | -21.91% |
| 2015 FY | -13.4 Million USD | -156.58% |
| 2015 Q3 | -3.3 Million USD | 3.54% |
| 2015 Q4 | -5.49 Million USD | -66.34% |
| 2015 Q1 | -1.19 Million USD | 71.47% |
| 2015 Q2 | -3.42 Million USD | -186.36% |
| 2014 FY | -5.22 Million USD | 0.0% |
| 2014 Q4 | -4.18 Million USD | 0.0% |
| 2014 Q2 | -178 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| uniQure N.V. | -282.87 Million USD | -82.165% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -969.068% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -429.28% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | -31.624% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -86.696% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -324.125% |
| Imunon, Inc. | -21.03 Million USD | -2350.216% |
| Dynavax Technologies Corporation | -37.02 Million USD | -1291.625% |
| Editas Medicine, Inc. | -169.18 Million USD | -204.58% |
| FibroGen, Inc. | -281.81 Million USD | -82.847% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | -11.884% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -1216.096% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 305.377% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -92.399% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -9679.674% |
| Verastem, Inc. | -92.08 Million USD | -459.588% |
| Zoetis Inc. | 3.06 Billion USD | 116.79% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 111.963% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -88.059% |
| Homology Medicines, Inc. | -48.25 Million USD | -967.85% |
| Nektar Therapeutics | -137.42 Million USD | -274.962% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -411.064% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -1053.628% |
| Perrigo Company plc | 151.9 Million USD | 439.23% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -231.243% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 96.339% |
| Illumina, Inc. | -1.06 Billion USD | 51.797% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 107.513% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 126.064% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -365.842% |
| Waters Corporation | 817.67 Million USD | 163.019% |
| Biogen Inc. | 1.29 Billion USD | 139.736% |
| Evolus, Inc. | -49.23 Million USD | -946.637% |
| Adicet Bio, Inc. | -152.03 Million USD | -238.923% |
| bluebird bio, Inc. | -244.26 Million USD | -110.958% |
| Geron Corporation | -193.94 Million USD | -165.691% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | -82.614% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -601.133% |
| Myriad Genetics, Inc. | -123.7 Million USD | -316.565% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 147.393% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -1043.127% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 365.011% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 112.732% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 138.17% |
| OPKO Health, Inc. | -157.02 Million USD | -228.167% |
| Exelixis, Inc. | 170.88 Million USD | 401.543% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 580.314% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -824.189% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -122.276% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | -45.674% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 252.645% |
| Blueprint Medicines Corporation | -486.27 Million USD | -5.967% |
| Insmed Incorporated | -709.62 Million USD | 27.386% |
| TG Therapeutics, Inc. | 20.63 Million USD | 2597.412% |
| Incyte Corporation | 620.52 Million USD | 183.041% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 29.062% |